Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by Possibleidiot01on Jun 25, 2021 4:33pm
181 Views
Post# 33452073

RE:Fire the management team

RE:Fire the management teamYou seem impatient .
Imagine how thes people feel - $4.65 a share.

MONTREAL, Feb. 1, 2021 /CNW/ - Persistence Capital Partners II, L.P. and Persistence Capital Partners II (International), L.P. (collectively, the "PCP Funds") today announced that on Friday, January 29, 2021, the PCP Funds acquired ownership of an aggregate of 4,696,874 common shares ("Common Shares") in the capital of Think Research Corporation ("Think") (TSXV: THNK), a company with a head office at 351 King Street East, Suite 500, Toronto, Ontario, M5A 0L6.

The Common Shares were issued to the PCP Funds in connection with the acquisition by Think on January 29, 2021 (the "Transaction") of all of the issued and outstanding shares of mdBriefCase Group Inc. ("MDB") from the PCP Funds and Jason Flowerday (the PCP Funds and Jason Flowerday collectively referred to as the "Sellers") pursuant to the terms and conditions of a share purchase agreement between Think, the Sellers, MDB and PCP GP, L.P. (as Seller Agent) dated January 18, 2021, as amended on January 29, 2021 (the "Share Purchase Agreement").

As part of the purchase price payable under the Share Purchase Agreement, the PCP Funds were issued an aggregate of 4,696,874 Common Shares (27,888 of which are being held in escrow by Think) at a deemed value of $4.65 per Common Share, representing approximately 11.41% of the issued and outstanding Common Shares. Prior to closing of the Transaction, the PCP Funds did not own, directly or indirectly, or exercises control or direction over any securities of Think.


<< Previous
Bullboard Posts
Next >>